Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, today announced that its subsidiary, Pearsanta, Inc., has submitted a grant application to the Prostate Cancer Research Program (“PCRP”) under the Department of Defense (“DoD”) Implementation Science Award funding mechanism. Pearsanta is seeking $2 million in non-dilutive funding to advance the early detection and management of prostate cancer. The Science Award, if granted, is expected to provide Pearsanta with sufficient funds to evaluate the Mitomic(R) Prostate Test (“MPT(TM)”) in a randomized clinical trial (“RCT”) to determine its effectiveness in better identifying men with high PSA levels who would have clinically significant prostate cancer. According to the announcement, the MPT has shown robust diagnostic performance for clinically significant prostate cancer.
“The MPT(TM) has the potential to significantly improve clinical outcomes by reducing unnecessary biopsies and enabling the early detection of prostate cancers. As we advance the validation of the MPT(TM) for clinical use and position it as a laboratory-developed test, we are confident that this innovation, if successful, will transform prostate cancer diagnostics and improve patient outcomes globally,” said Christopher Mitton, President of Pearsanta.
To view the full press release, visit https://ibn.fm/cEtYX
About Aditxt Inc.
Aditxt is focused on discovering, developing and deploying promising health innovations. Aditxt’s diverse portfolio includes Adimune(TM), developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity and allergies; Adivir(TM), focused on identifying, developing and commercializing new ways to treat infectious diseases; and Pearsanta(TM), offering timely, convenient and high-quality personalized lab testing anytime and anywhere, backed by its CLIA-certified and CAP-accredited monitoring center. For more information, visit the company’s website at www.Aditxt.com.
NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]
InvestorWire is powered by IBN